• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Buyouts

Bridgepoint acquires Oasis Healthcare from Duke Street

  • Carmen Reichman
  • @carmenreichman
  • 02 April 2013
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Bridgepoint Capital has acquired UK-based private dental healthcare provider Oasis Healthcare in a £185m secondary buyout from Duke Street.

The price corresponds to an entry multiple of just over 9x, according to the target's EBITDAE of £17.8m for the 2011/2012 financial year.

The sale was initiated by Duke Street, which hired DV Advisory to find a buyer. The business is said to have attracted widespread interest from private equity houses, which are believed to have included LDC, Capvest and Omers Private Equity.

Oasis Healthcare

  • DEAL:

    SBO

  • VALUE:

    £185m

  • DEBT RATIO:

    £146.5m

  • LOCATION:

    Norwich

  • SECTOR:

    Healthcare providers

  • FOUNDED:

    1996

  • TURNOVER:

    £148.1m

  • EBITDA:

    £17.8m (EBITDAE)

  • STAFF:

    2,000

  • VENDOR:

    Duke Street Capital

Duke Street reinvested part of the sale's proceeds to retain a minority stake in Oasis. The GPs expect further rapid expansion for the business, Bridgepoint said in a statement.

Debt
Total banking facilities of £146.5m were arranged by Bank of Ireland, Barclays, GE Capital, HSBC, ING and Société Générale. Bridgepoint committed a further £60m in capex facilities for the business's expansion. 

Previous funding
Duke Street took Oasis private at the end of 2007, following a bidding war with ADP Healthcare. The GP paid 12x EBITDA for the asset according to unquote" data.

The GP's final bid was 94p per share, reflecting an enterprise value of £125.5m for the business. The share price represented a 100% premium on the closing price prior to the commencement of the offer period. The deal was supported by a £70.4m debt package from Barclays and comprised £55m of senior debt and a £15.4m mezzanine tranche.

Duke Street bought Foresight Venture Partners' 10% stake in Oasis for £8m as part of the take-private. Foresight realised returns of 5.1x capital invested on behalf of its VCT 3 and 4 vehicles. Duke Street's acquisition also enabled Singer & Friedlander, Chelverton and Beringea (via its ProVen VCT) to exit.

In 2010, Oasis received a further £30m financing from Duke Street (£10m) and Partners Group (£20m) alongside £20m of growth capital, which was extracted from the company's operating cashflow. Oasis used the capital to fund expansion including upgrading its existing estate, acquiring established dental practices and building new sites.

The business had 134 dental practices in England and Wales at the time of the delisting. By 2013, it had more than 200 practices across England, Wales and Northern Ireland.

Company
Oasis is a private dental care provider active across the UK. The business was founded in 1996 and is headquartered in Norwich. It serves both the NHS and private patients.

In the financial year 2011/12, Oasis had a turnover of £148.1m (up from £135.6m in the year before and £96m in 2007) and an EBITDAE of £17.8m, up from £15.9m in the year prior and £11m in 2007. The company invested £7.7m in new builds, acquisitions and existing facilities in the period.

People
Jamie Wyatt is a partner at Bridgepoint. Peter Taylor is Duke Street's managing partner.

Advisers
Equity – Rothschild (Corporate finance); KPMG (Financial due diligence, tax, pensions due diligence, IT due diligence); PwC (Commercial due diligence); Linklaters (Legal); Marsh (Insurance due diligence).
Vendor – DC Advisory (Corporate finance); PwC (Financial due diligence); LEK Consulting (Commercial due diligence); SJ Berwin (Legal).
Debt – Clifford Chance (Legal).
Management – Jamieson (Financial due diligence); Burges Salmon (Legal). 

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Buyouts
  • Exits
  • UK / Ireland
  • Healthcare
  • Bridgepoint
  • United Kingdom
  • Duke Street Capital
  • Secondary buyout

More on Buyouts

Clinical trials and biotechnology
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • Buyouts
  • 04 September 2023
EMEA Public to Private M&A
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • Investments
  • 04 September 2023
HR software solutions providers
Main Capital’s Assessio to be sold to Pollen Street

Recruitment software company tripled in revenue under Main Capital’s ownership

  • Buyouts
  • 25 August 2023
Ice cream
Exponent divests ‘significant' stake in Meadow to Canadian investor

Since 2018, GP has diversified food ingredients company's focus beyond commodity dairy

  • Exits
  • 22 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013